Investigator Sponsored Studies, grants and sponsorships
Vertex Pharmaceuticals funds independent research and studies advancing science and patient care in cystic fibrosis, pain, IgA nephropathy, and related diseases.
Funder: Vertex Pharmaceuticals
Due Dates: Rolling (most programs) | RFP window (beta thalassemia & sickle cell disease only)
Funding Amounts: No strict cap; requests should represent fair market value. Up to $750,000 over 3 years for select CF programs; general guidance is not to exceed 30% of an organization’s annual operating budget.
Summary: Supports investigator-sponsored studies, research grants, and sponsorships advancing care and scientific knowledge in cystic fibrosis, pain, IgA nephropathy, and other Vertex focus areas.
Key Information: Requests must be submitted at least 60 days before event start; rolling submissions except for certain RFP-limited areas.
Description
Vertex Pharmaceuticals offers a flexible funding program supporting independent research, education, and advocacy initiatives that align with their therapeutic focus areas, especially cystic fibrosis, pain, IgA nephropathy, beta thalassemia, and sickle cell disease. Funding is available for investigator-sponsored studies (ISS), independent medical education, patient advocacy, organizational sponsorships, and collaborative clinical research. The program aims to advance scientific understanding, improve patient care, and foster innovation in areas of unmet medical need.
